Dec 8 2009
LinkMed’s (STO:LMED) subsidiary AbSorber has received patent protection
for its transplantation cross match-test XM-ONE® in the European
countries. The patent was previously approved in New Zealand which was
the first country to approve a patent for AbSorbers product. The
European countries are highly prioritized markets for AbSorber and the
patent approval is an important milestone in Absorbers intellectual
property strategy.
The patent was granted by the European Patent Office (EPO) and AbSorber
has also patent applications pending for XM-ONE® in the US, Japan and in
other key transplantation markets. The company expects more countries to
follow the European approval of the XM-ONE® patent.
XM-ONE® is unique in that it is the first standardized test that can
detect antibodies against the cells that line the inside of blood
vessels. These endothelial cells are the first point of contact between
the transplanted organ and the recipient’s immune system.
Anti-endothelial cell antibodies have been shown to play a key role in
causing post-transplantation rejections.
http://www.cisionwire.com
._3D_illustration_-_Illustration_-_Tatiana_Shepeleva_A1_83483dd4faee4b1c80ffcb34e563db93-80x70.jpg)
Novel monoclonal antibodies show promise in preventing severe mpox disease